9/4/2021 Nightingale Health Plc’s subsidiary received clinical laboratory certification in Japan
31/3/2021 The cancellation of Nightingale Health Plc’s treasury shares entered in the Trade Register
25/3/2021 Nightingale Health Plc’s ten largest shareholders after the completion of the initial public offering
23/3/2021 Stabilisation measures taken and the end of the stabilisation period; the Board of Directors has resolved on the cancellation of treasury shares
18/3/2021 The IPO of Nightingale has been oversubscribed and the listing will be completed as planned – trading in the series B shares is expected to commence on 19 March 2021
16/3/2021 Public offering of Nightingale has been oversubscribed and therefore the subscription period has been discontinued
15/3/2021 Nightingale Health Plc comments on the media coverage on its initial public offering
8/3/2021 Nightingale announces a fixed subscription price and publishes a prospectus for its contemplated IPO and listing of its series B shares on Nasdaq First North Growth Market Finland
8/3/2021 Nightingale has applied for its series B shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering